- Home
- FSP vs MOLN Comparison
FSP vs MOLN Comparison
Compare FSP & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FSP | MOLN |
|---|---|---|
| Founded | 1981 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.4M | 164.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | FSP | MOLN |
|---|---|---|
| Price | $0.93 | $4.22 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.75 |
| AVG Volume (30 Days) | ★ 481.0K | 3.9K |
| Earning Date | 02-10-2026 | 02-11-2026 |
| Dividend Yield | ★ 4.28% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $109,497,000.00 | N/A |
| Revenue This Year | $4.36 | N/A |
| Revenue Next Year | $0.81 | $999.99 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.85 | $3.36 |
| 52 Week High | $2.09 | $5.91 |
Technical Indicators
Market Signals| Indicator | FSP | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 43.06 | 48.42 |
| Support Level | $0.87 | $4.16 |
| Resistance Level | $0.95 | $4.44 |
| Average True Range (ATR) | 0.06 | 0.18 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 46.90 | 44.12 |
Price Performance
Historical ComparisonAbout FSP Franklin Street Properties Corp.
Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The company's operations include rental income from real estate leasing, interest income from secured loans made on office properties, property dispositions, and fee income from asset/property management and development. Franklin Street markets Atlanta, Dallas, Denver, Houston, and Minneapolis.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.